What if the biggest cause of cancer isn’t just sugar, stress, or genetics — but hidden infections and toxins no one is testing for?

In this hard-hitting episode, Dr. Dino Prato, founder of Envita Medical Centers, unpacks the real root causes of cancer — and why so many go undetected by conventional medicine. Backed by 25+ years of treating advanced cases, he explains how infections, chemical toxins, immune dysfunction, mitochondrial failure, and chronic stress create the perfect storm for cancer development and resistance.

🎯 What You’ll Learn:

• Why cancer is often driven by both mitochondrial damage and mutations
• The role of infections like Epstein-Barr, HHV-6, Lyme, and fungal mycotoxins
• How stress, trauma, and emotional toxicity impact immune function
• Why gut health, nutrient density, and mitochondrial repair are critical for healing
• How early screening, detoxification, and targeted nutrition support prevention and recovery
  
  

If you’ve ever wondered what caused your cancer — or how to lower your risk — this episode offers the roadmap.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

What if your cancer is so hard to treat... because no one’s targeting the real causes?

In this deep-dive episode, Dr. Dino Prato, founder of Envita Medical Centers, explains the true nature of treatment resistance in cancer — and why standard care often falls short. From mutations and mitochondrial dysfunction to hidden infections and immune evasion, most patients are only getting a fraction of the story.

🎯 What You’ll Learn:

• Why cancer is biphasic: mitochondrial and mutational drivers
  
  
• How toxins, infections (like EBV, Lyme, fungi), and hypoxia feed cancer
  
  
• Why standard chemo may actually cause resistance and immune collapse
  
  
• How DAMPs, NK cells, and targeted chemo can flip the immune system back on
  
  
• The role of precision testing: RNA, spatial biology, tumor microenvironment
  
  
• How interventional radiology (TACE) delivers chemo directly to tumors with less damage
  
  

📊 In our clinical experience, patients receiving precision-based, low-dose, and interventional therapies have shown reduced side effects, improved outcomes, and better quality of life.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

What if the biggest risk of chemotherapy isn’t the cancer… but what it does to your immune system?

In this eye-opening episode, Dr. Dino Prato, founder of Envita Medical Centers, explains why conventional chemotherapy — especially when given at maximum tolerated doses — may increase the risk of long-term immune suppression, inflammation, and even resistance.

🧬 Discover how genetically targeted, low-dose chemotherapy (also known as metronomic or fractionated chemotherapy) is designed to support immune function while precisely attacking tumors.

🎯 What You’ll Learn:

• Why standard chemo protocols often don’t match the patient’s unique molecular profile
• The role of DAMPs (Damage-Associated Molecular Patterns) in immune signaling
• How combining genomics, transcriptomics, immune profiling, and targeted delivery methods may reduce toxicity and improve outcomes
• When interventional delivery (chemo directly to the tumor) might offer better precision
• Why timing, dosage, and recovery planning are critical to treatment success
  
  

At Envita, we believe better data leads to smarter, more immune-friendly cancer care — especially for patients who’ve already failed conventional options.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

Providing support and acting as a patient advocacy is an incredible act of love for a cancer patient or anyone facing chronic pain. Navigating medical decision making can be overwhelming, but remember you're not alone. Our team provides patient care and advocacy to help guide you.

Supporting someone with cancer? You're not alone. And your role could change everything.

In this heartfelt episode, Dr. Dino Prato, founder of Envita Medical Centers, shares a message for spouses, children, friends, and caregivers acting as advocates for someone facing cancer. If you're overwhelmed by medical choices, insurance limits, or unclear next steps — this is for you.

👥 What You’ll Learn:

• Why advocates are often the ones who ask the right questions
• The dangers of one-size-fits-all cancer care
• How precision targeting (DNA, RNA, immune profiling) can uncover personalized treatment options
• What to consider when navigating costs, insurance, and non-covered options
• The importance of testing before treatment — and slowing down rushed decisions
  
  

🔬 Precision care isn’t just about using more tools — it’s about using the right ones for each patient. That’s how Envita has helped thousands of patients who’ve failed conventional care find renewed options, and in many cases, improved quality of life.

🎯 “The best care is the one that’s best targeted for the individual.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

Many believe cancer immunotherapy is a guaranteed solution, but the reality in oncology is that strong responses only occur in a minority of patients. This highlights the need for personalized medicine approaches, focusing on precision oncology to improve cancer treatment outcomes, according to a medical oncologist. Further research in immunology is crucial.

Why do only 1 in 5 cancer patients respond to immunotherapy?
In this critical episode, Dr. Dino Prato, founder of Envita Medical Centers, reveals the deeper science behind why PD-1 and PD-L1 checkpoint inhibitors often fail — and how precision immunotherapy may dramatically change that outcome.

Checkpoint inhibitors are powerful, but for most patients, the response doesn’t last — or never starts. This doesn’t mean immunotherapy is broken. It means most patients aren’t receiving care that’s truly customized to their tumor’s immune environment.

🎯 What You’ll Learn:

• Why “cold tumors” block T cells from doing their job
• How spatial biology, immune profiling, and antigen mapping help personalize immunotherapy
• What immune exhaustion looks like — and how to reverse it
• Why combining genomics, transcriptomics, and natural killer (NK) cell therapy can improve tumor visibility
• How precision immunotherapy is helping patients aim beyond temporary response — and toward long-term remission
  
  

In our clinical experience, using N-of-1 mapping has enabled more durable responses by removing guesswork and guiding treatment with real-time immune data.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

Dr. Dino Prato introduces circulating tumor cells, or CTCs, a promising biomarker in cancer diagnosis. This method gives oncologists insight into a patient's prognosis and can guide precision medicine for cancer treatment. Learn how CTCs from a simple ctc blood tests can reshape cancer care and help you track cancer progression and treatment response?

In this episode, Dr. Dino Prato discusses the science behind Circulating Tumor Cell (CTC) testing—an emerging tool that may provide insight into tumor behavior, treatment response, and disease progression.

🔬 What You’ll Learn:

• What CTCs are and how they enter the bloodstream
• Why CTC levels may correlate with prognosis (per peer-reviewed studies)
• How CTC data is used alongside genomics, immune profiling, and transcriptomics at Envita Medical Centers
• Limitations of conventional oncology in adopting new technologies
  
  

⚠️ CTC testing is not FDA-approved as a standalone diagnostic tool and should not replace conventional imaging or biopsy. It is used as part of a broader integrative care model.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

Exciting advancements in cancer treatment are showing promising results. A new study reveals a significant improvement in "quality of life" for stage 4 cancer patients. The new "treatment" also had fewer "side effects". This "cancer research" could give hope to those experiencing severe "cancer symptoms". Visit our "cancer center" for more information. envita.com

What if cancer treatment didn’t have to come with hair loss, exhaustion, and hopeless odds?

In this groundbreaking episode, Dr. Dino Prato shares how precision oncology is changing the game — with a 2024 peer-reviewed study* that found 72% of late-stage cancer patients treated with Envita’s personalized protocols experienced response or disease stability—35x higher than response rates reported for conventional palliative chemotherapy.

*View the research paper here:
https://www.scirp.org/journal/paperinformation?paperid=132493

🚀 Discover how Envita’s “N of 1” personalized approach uses over 1,000 data points to:

• Customize treatment for your DNA, RNA, immune profile & more
• Avoid overtreatment, reduce side effects, and improve outcomes
• Combine the best of integrative & conventional therapies, guided by data

Learn why one-size-fits-all cancer care is outdated — and how a new model is bringing health, and healing to patients who had no more options.

📊 Backed by real clinical results, advanced molecular targeting, and 25 years of innovation.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493

What if you could detect and treat breast cancer without surgery, radiation, or high-dose chemo — by catching it earlier than anyone else?

In this breakthrough episode, Dr. Dino Prato, founder of Envita Medical Centers, reveals the layered early detection system and precision-based strategies used by less than 1% of doctors. From blood-based multi-cancer testing to cryoablation, this is a new roadmap for prevention, early treatment, and long-term remission.

🎯 What You’ll Learn:

• How a simple blood test (ctDNA + CTC) can screen for 50+ cancers, including breast
• Why layering signals (imaging + molecular testing) leads to earlier and more accurate detection
• How cryoablation can remove small tumors without surgery
• The role of methylation scores, immune priming, and antigen visibility
• How to track remission through biomarkers — long before tumors return
• What most doctors miss: the connection between infections, toxins, and immune dysfunction
• Why breast cancer doesn’t always start with genetics — and what you can do about it

“When you use precision tools — not guesswork — you can treat earlier, avoid overtreatment, and restore the body’s immune function.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493